Search Results - cognitive+impairment

5 Results

Sort By:

SYNGAP antisense oligonucleotide as therapy for human cognitive disorders

Unmet Need: Recent human genetic studies have suggested that mutations in the SYNGAP1 gene are linked to intellectual disability (ID), autism spectrum disorders (ASD), neurodevelopmental disorders, high rates of epilepsy, and schizophrenia. SYNGAP1 is a gene that encodes SynGAP, a GTPase-activating protein that is highly enriched in nerve cells in the...

Published: 5/9/2024 | Inventor(s): Richard Huganir, Ingie Hong, Yoichi Araki

Keywords(s): Biologics, CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, Gene Therapy, Nucleic Acid, Single, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Psychiatry > Autism Spectrum Disorder, Clinical and Disease Specializations > Psychiatry > ADHD, Clinical and Disease Specializations > Psychiatry > Mood Disorders, Technology Classifications > Therapeutic Modalities > Gene Therapies

Acetylated Polyamines as Biomarkers of HIV-1 Associated Neurocognitive Disorders (HAND)

Acetylated Polyamines as Biomarkers of HIV-1 Associated Neurocognitive Disorders (HAND) Marketing Summary: Polyamines are molecules, present in all organisms, whose concentrations are regulated by the enzyme Spermine/Spermidine Acetyl transferase (SSAT). SSAT works by inactivating polyamines. Once these polyamines are inactivated they are...

Published: 5/9/2024 | Inventor(s): Kamel Khalili, Carlos Barrero, Salim Merali, Jay Rappaport, Norman Haughey, Ned Sacktor

Keywords(s): Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Cognitive Impairment, Diagnostic Biomarker, Disease Indication, HIV/AIDS, HIV-Associated Neurocognitive Disorders, In Vitro Diagnostics

Category(s): Clinical and Disease Specializations, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders

Prevention of Anesthetic-Induced Neurocognitive Dysfunction

Unmet NeedEvery year in the United States more than one million children under the age of five undergo a surgical procedure that requires anesthesia. Children who have had multiple early exposures to anesthesia are at greater risk of developing learning disabilities and disorders of attention and anxiety. Additionally, animal models that are exposed...

Published: 5/9/2024 | Inventor(s): Roger Johns, Michele Schaefer

Keywords(s): CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Psychiatry > Anxiety

Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs

Some glutamine antagonists have been shown to have anti-cancer activities in multiple preclinical and clinical studies. However the toxicity of the glutamine antagonists at doses necessary for their anticancer effects have hampered their clinical development. Herein we describe a completely novel use for the glutamine antagonists. Using a prototype...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, David Volsky, Kristen Hollinger, Michael Nedelcovych, Atsushi Kamiya

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, HIV/AIDS, HIV-Associated Neurocognitive Disorders, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities

C11355: Therapeutic Alleviating Cognitive Impairment from Multiple Sclerosis (MS)

Novelty:This technology is a first of its kind, potential therapeutic in alleviating cognitive impairment (CI) as a result of Multiple Sclerosis (MS) and related central nervous system (CNS) autoimmune diseases.Value Proposition:CI is a debilitating outcome of many CNS disorders, including MS. Currently, the high prevalence of CI and the extremely negative...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Kristen Hollinger, Adam Kaplin

Keywords(s): Antagonists/Inhibitors, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Cognitive Impairment, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Mechanism of Action Biomarker, Multiple CNS Indications, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities